Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...

Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with ...

What To Know: Novo Nordisk, one of Eli Lilly’s main competitors, announced a regulatory breakthrough for an oral weight loss drug. The FDA approved the company’s pill form of Wegovy, making it the ...

The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...

On December 22, 2025, we lost one of the few remaining members of the Greatest Generation. Helen (Morris) Blocker was born in the Bronx Borough of New York City on September 18, 1921. She attended the ...

One firm said Trump's executive order threatens "the legal system itself." Federal judges in D.C. on Friday partially blocked two executive orders signed by President Donald Trump targeting the Jenner ...

AdGuard’s 5-Year VPN Bundled With an Ad Blocker Can Be Your for Just $35 Encrypt your connection, bypass geo-restrictions, and clean up ads across nine devices for a discounted price.

Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from ...

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the company's lead in this niche of the industry. Even after their strong run, Lilly's ...